NASDAQ$VERV
Verve Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Verve Therapeutics reported financial results for the first quarter of 2022 and outlined its global development strategy for VERVE-101.
Verve Therapeutics announced the clearance of its first VERVE-101 clinical trial application and outlined its global clinical development strategy. The company's cash, cash equivalents, and marketable securities totaled $323.3 million, providing a cash runway into 2024. Net loss for the quarter was $30.2 million, or $0.62 per share.
- Received clearance for first VERVE-101 clinical trial application in New Zealand.
- Plans to initiate a Phase 1 clinical trial in HeFH patients in New Zealand in mid-2022, with initial clinical data expected in 2023.
- Preparing to submit regulatory filings for VERVE-101 in the United Kingdom and United States in the second half of 2022.
- Cash, cash equivalents, and marketable securities of $323.3 million provide cash runway into 2024.
Headline financials
Revenue & EPS history
Verve Therapeutics · Revenue · Quarterly
$33M
Revenue by segment
Verve Therapeutics · $3.12M total across 1 segment · Q3 2023
- Collaboration Revenue$3.12M—100.0%
Forward guidance
Verve Therapeutics is focused on advancing its VERVE-101 program and expanding its pipeline. The company anticipates initiating clinical trial sites and patient enrollment in the respective regions shortly following clearance of its applications, should they be accepted.
Tailwinds
- Initiate a first-in-human Phase 1 clinical trial in patients with HeFH in mid-2022.
- Submit both a CTA in the United Kingdom and an investigational new drug (IND) application in the United States in the second half of 2022.
- Complete IND-enabling studies in the third quarter.
- Advance its product-focused pipeline.
- Identify new targets to address.
Headwinds
- Risks associated with the company’s limited operating history
- The timing of and the company’s ability to submit applications for, its product candidates
- Advance its product candidates in clinical trials
- Correctly estimate the potential patient population and/or market for the company’s product candidates
- Replicate in clinical trials positive results found in preclinical studies and/or earlier-stage clinical trials of VERVE-101 and its other product candidates
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2022
-1.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-3.8%
Avg return
30 days after
47%
8 / 17 earnings
Positive
+24.4%
Q4 2023
Best reaction
-34.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +3.4% | +5.0% | +48.1% | |
| Q4 2025 | -1.7% | -2.9% | -16.3% | |
| Q3 2024 | +6.0% | +4.5% | +1.0% | |
| Q2 2024 | -12.1% | -20.8% | -1.6% | |
| Q1 2024 | +3.2% | +0.8% | -15.6% | |
| Q4 2023 | +24.4% | +12.7% | -8.2% | |
| Q3 2023 | +11.8% | +4.8% | -13.8% | |
| Q2 2023 | +2.6% | -9.9% | -28.0% | |
| Q1 2023 | -5.2% | -4.5% | -2.6% | |
| Q4 2022 | +7.0% | +3.0% | -20.8% | |
| Q3 2022 | -34.2% | -13.7% | -31.5% | |
| Q2 2022 | +17.5% | +31.2% | +47.0% | |
| Q1 2022 | -4.4% | +12.8% | +15.2% | |
| Q4 2021 | -20.1% | -4.3% | -19.7% | |
| Q3 2021 | -2.7% | -7.8% | -34.7% | |
| Q4 2020 | -1.4% | +5.5% | +7.5% | |
| Q2 2021 | -10.7% | -11.9% | +10.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro